Dr. Petra Davelaar
Dr. Tyler LeBaron
Victor Sagalovsky
Dr. Stephanie Seneff
Robert Slovak
Tyler W. LeBaron, Ph.D., is the Founder and Executive Director of the science-based, nonprofit, Molecular Hydrogen Institute. His background is in biochemistry, physiology, and exercise science. He has taught physiology, and currently teaches exercise physiology and chemistry lab classes at Southern Utah University as an adjunct instructor.
He Interned at Nagoya University Japan in the department of Neurogenetics to research the molecular mechanisms of hydrogen gas on cell-signaling pathways. He is a director of the International Hydrogen Standards Association (IHSA) and the International Molecular Hydrogen Association (IMHA). He speaks at medical conferences in the US for doctors CMEs/CEUs, and at academic biomedical hydrogen symposia and conferences around the world. He is also a member of the Academic Committee of Taishan Institute for Hydrogen Biomedical Research.
He collaborates with researchers at home and abroad, and helps advance the education, research, and awareness of hydrogen as a potential therapeutic medical gas. When not doing research, he is often found training and competing in running and recently as a competitive arm wrestler.
Dr. Petra Davelaar
Dr Gábor Somlyai graduated as a biologist at the University of Szeged in 1982. Between 1982 and 1990 he worked for the Department of Plant Pathology, Plant Protection Institute of the Hungarian Academy of Sciences. From 1983 to 1986 he had a scholarship of the Hungarian Academy of Sciences as a postgraduate student for obtaining PhD. He defended his thesis in molecular biology in 1988. In the same year Dr. Somlyai spent six months at the Georg-August University in Göttingen on a DFG scholarship.
From the end of 1988 he held a postdoctoral fellowship at the University of Missouri (Columbia, Missouri, USA), where he worked in the field of genetic engineering and gene mapping. In the wake of the Hungarian, Nobel-prize winning scientist Albert Szent-Györgyi,– who said that the true cause of cancer should be looked for at the submolecular level – Dr. Somlyai began his investigations of the biological importance of naturally occurring deuterium as a senior research fellow at the Hungarian Institute of Oncology in 1990. In 1993 he established HYD LLC. for Cancer Research and Drug Development to carry out research and drug development based on the proprietary procedure, deuterium depletion.
Dr. Somlyai served as the scientific director of HYD LLC. between 1993 and 1997 before becoming the CEO of the company. Since 2012, he is the general director of HYD’s parent company, HYD Pharma Inc. His first book, Defeating Cancer! was published in Hungary in 2000, since then it has been published in several other countries. His second book entitled „Deuterium Depletion – A New Way in Curing Cancer and Preserving Health” appeared in Hungary in 2021, the English version of the book came out in February 2022. The Japanese, Chinese, Korean and Russian editions of the book are expected to be published by the end of 2022. Gábor Somlyai is a holder of numerous international patents, and author of more than 50 scientific publications, and is a highly sought-after speaker at international conferences.
Dr. Seneff is a Senior Research Scientist at MIT’s Computer Science and Artificial Intelligence Laboratory in Cambridge, Massachusetts, USA. She has a BS degree from MIT in biology and a PhD from MIT in electrical engineering and computer science. Her recent interests have focused on the role of toxic chemicals and micronutrient deficiencies in health and disease, with a special emphasis on the pervasive herbicide glyphosate, and the mineral, sulfur.
Since 2008, she has authored over three dozen peer-reviewed journal papers on these topics. She is writing a book on glyphosate, titled “Toxic Legacy: How the Weedkiller Glyphosate Is Destroying Our Health and the Environment,” which is expected to be released by Chelsea Green publishers in June 2021.
Professor of Pediatrics at the University of California Los Angeles (UCLA) School of Medicine, the Co-Director of the Stable Isotope Research Laboratory at the Lundquist Institute for Biomedical Innovations (LUNDQUIST) and Investigator at the Clinical and Translational Research Institute at the Harbor-UCLA Medical Center with a primary focus on studying cancer cell metabolism.
Dr. Boros is an internationally recognized expert of metabolic water biochemistry as well as deuterium mediated kinetic isotopic effects in health and disease, which are translational fields of Deutenomics in medicine.
Dr. Boros created the term Deutenomics which is the new science of autonomic deuterium discrimination in nature.
Dr. Olgun is a professor and founding dean of pharmacology at Istinye University, Istanbul. He completed his MD and with emphasis on clinical biochemistry at Gülhane Military Medical University.
He has studied the molecular mechanisms of aging by using cellular senescence and C. elegans models in Huffington Center on Aging Baylor College of Medicine Houston USA and completed a Ph.D in pharmaceutical botany. He worked as a laboratory supervisor in various public and private hospitals, and founded one.
He has developed patented and commercialized products within the R & D company of which he is a founding partner in Antalya Technopolis. His interest in deuterium started when he became aware of the high natural abundance of deuterium and its concentrations in living organisms. In 2007 he published his pivotal findings that show how deuterium damages ATP synthase nanomotors. He has numerous international and national publications and book editing, with over 500 citations, most of them being in the field aging.
